How is EGFR-mutant lung cancer treated when it causes leptomeningeal metastasis?

Leptomeningeal metastasis (LM) means cancer has spread into the fluid and thin layers that surround the brain and spinal cord. It is a serious complication, and it shows up often in people whose lung cancer has an EGFR mutation, a change in a gene that drives tumor growth ⁹¹⁰¹¹. The short answer from the research: drugs that get into the brain fluid matter most. Osimertinib, a targeted EGFR drug, is a common backbone, and adding bevacizumab or using pemetrexed has been linked to longer survival in some studies ⁹¹¹. Most of this evidence comes from small, retrospective studies (looking back at past patient records), not large randomized trials, so the picture is promising but not settled.

What the research says

Osimertinib is central to treatment. In a review of 62 patients with EGFR-mutant lung cancer and LM, those treated with osimertinib had a median intracranial progression-free survival (time before the cancer grew in the brain) of 6.43 months and a median overall survival of 9.37 months ¹⁰. That study also found survival was similar across different sensitive EGFR mutations, meaning the specific mutation type did not seem to change how well osimertinib worked ¹⁰. It also noted that patients who received whole-brain radiation therapy after LM had numerically higher survival, though this was not a firm statistical finding ¹⁰.

What to ask your doctor

• Which treatments work best for my specific EGFR mutation and my LM, and is osimertinib an option for me?
• Would adding bevacizumab to my EGFR targeted drug be worth considering, and what are the tradeoffs?
• Is pemetrexed or another chemotherapy something I should discuss, given what the studies show about survival?
• Would whole-brain radiation therapy play a role in my case, and how does it fit with drug treatment?
• What signs of LM progression should I watch for, and how often will we check my brain and spinal fluid?